{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:59:33Z","timestamp":1794502773694,"version":"4.9.1"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To estimate whether methadone, buprenorphine, or detoxification treatment is the most cost-effective approach to the management of opioid use disorder (OUD) during pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We created a decision analytic model that compared the cost effectiveness (eg, the marginal cost of the strategy in U.S. dollars divided by the marginal effectiveness of the strategy, measured in quality-adjusted life-years [QALYs]) of initiation of methadone, buprenorphine, or detoxification in treatment of OUD during pregnancy. Probabilities, costs, and utilities were estimated from the existing literature. Incremental cost-effective ratios for each strategy were calculated, and a ratio of $100,000 per QALY was used to define cost effectiveness. One-way sensitivity analyses and a Monte Carlo probabilistic sensitivity analysis were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Under base assumptions, initiation of buprenorphine was more effective at a lower cost than either methadone or detoxification and thus was the dominant strategy. Buprenorphine was no longer cost effective if the cost of methadone was 8% less than the base-case estimate ($1,646\/month) or if the overall costs of detoxification were 121% less than the base-case estimate for the detoxification cost multiplier, which was used to increase the values of both inpatient and outpatient management of detoxification by a factor of 2. Monte Carlo analyses revealed that buprenorphine was the cost-effective strategy in 70.5% of the simulations. Direct comparison of buprenorphine with methadone demonstrated that buprenorphine was below the incremental cost-effective ratio in 95.1% of simulations; direct comparison between buprenorphine and detoxification demonstrated that buprenorphine was below the incremental cost-effective ratio in 45% of simulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Under most circumstances, we estimate that buprenorphine is the cost-effective strategy when compared with either methadone or detoxification as treatment for OUD during pregnancy. Nonetheless, the fact that buprenorphine was not the cost-effective strategy in almost one out of three of simulations suggests that the robustness of our model may be limited and that further evaluation of the cost-effective approach to the management of OUD during pregnancy is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003503","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T11:39:00Z","timestamp":1570707540000},"page":"921-931","source":"Crossref","is-referenced-by-count":19,"title":["Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder"],"prefix":"10.1097","volume":"134","author":[{"given":"Ashish","family":"Premkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Grobman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishka","family":"Terplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230925","doi-asserted-by":"crossref","first-page":"846","DOI":"10.15585\/mmwr.mm6731a1","article-title":"Opioid use disorder documented at delivery hospitalization \u2013 United States, 1999-2014","volume":"67","author":"Haight","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20230925","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs","volume":"372","author":"Tolia","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20230925","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/AOG.0000000000002054","article-title":"Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation","volume":"130","author":"Reddy","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R5-20230925","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/jp.2015.36","article-title":"Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009\u20132012","volume":"35","author":"Patrick","year":"2015","journal-title":"J Perinatol"},{"key":"R6-20230925","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Opioid use and opioid use disorder in pregnancy. Committee Opinion No. 711. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R7-20230925","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","article-title":"Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts","volume":"132","author":"Schiff","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R8-20230925","doi-asserted-by":"crossref","first-page":"B5","DOI":"10.1016\/j.ajog.2019.03.022","article-title":"Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine","volume":"221","author":"Ecker","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20230925","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ajog.2016.03.015","article-title":"Detoxification from opiate drugs during pregnancy","volume":"215","author":"Bell","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R10-20230925","first-page":"854","article-title":"Opioid detoxification in pregnancy","volume":"92","author":"Dashe","year":"1998","journal-title":"Obstet Gynecol"},{"key":"R11-20230925","doi-asserted-by":"crossref","first-page":"267.e1","DOI":"10.1016\/j.ajog.2013.05.026","article-title":"The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy","volume":"209","author":"Stewart","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20230925","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/AOG.0000000000002562","article-title":"Opioid detoxification during pregnancy: a systematic review","volume":"131","author":"Terplan","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R13-20230925","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/0002-9378(73)90953-8","article-title":"Narcotic withdrawal in pregnancy: stillbirth incidence with a case report","volume":"116","author":"Rementeri\u00e1","year":"1973","journal-title":"Am J Obstet Gynecol"},{"key":"R14-20230925","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0002-9378(75)90613-4","article-title":"Fetal stress from methadone withdrawal","volume":"122","author":"Zuspan","year":"1975","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20230925","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0272989X9701700205","article-title":"Primer on medical decision analysis: part 5\u2014working with Markov processes","volume":"17","author":"Naimark","year":"1997","journal-title":"Med Decis Making"},{"key":"R17-20230925","first-page":"313","article-title":"Using triangular distribution for business and finance simulations in excel","volume":"42","author":"Fairchild","year":"2016","journal-title":"J Finan Educ"},{"key":"R18-20230925","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-20230925","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/08897077.2016.1146649","article-title":"Factors associated with buprenorphine versus methadone use in pregnancy","volume":"37","author":"Krans","year":"2016","journal-title":"Subst Abus"},{"key":"R20-20230925","first-page":"1","article-title":"Sublingual and transmucosal buprenorphine for opioid use disorder: review and update","volume":"15","year":"2016","journal-title":"Advisory"},{"key":"R23-20230925","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1360-0443.2000.95710557.x","article-title":"One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme","volume":"95","author":"Hutchinson","year":"2000","journal-title":"Addiction"},{"key":"R24-20230925","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drugalcdep.2006.12.019","article-title":"Overdose after detoxification: a prospective study","volume":"89","author":"Wines","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R25-20230925","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drugpo.2017.05.039","article-title":"Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone","volume":"46","author":"Kelty","year":"2017","journal-title":"Int J Drug Policy"},{"key":"R26-20230925","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"R27-20230925","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"R28-20230925","first-page":"1","article-title":"Births: final data for 2016","volume":"67","author":"Martin","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"R29-20230925","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10995-016-2190-y","article-title":"The Prevalence and impact of substance use disorder and treatment on maternal obstetric experiences and birth outcomes among Singleton deliveries in Massachusetts","volume":"21","author":"Kotelchuck","year":"2017","journal-title":"Matern Child Health J"},{"key":"R30-20230925","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamapediatrics.2017.5195","article-title":"Association of rooming-in with outcomes for neonatal abstinence syndrome: a systematic review and meta-analysis","volume":"172","author":"MacMillan","year":"2018","journal-title":"JAMA Pediatr"},{"key":"R31-20230925","doi-asserted-by":"crossref","first-page":"pii: e20173520","DOI":"10.1542\/peds.2017-3520","article-title":"Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014","volume":"141","author":"Winkelman","year":"2018","journal-title":"Pediatrics"},{"key":"R35-20230925","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jsat.2017.07.008","article-title":"Monetary conversion factors for economic evaluations of substance use disorders","volume":"81","author":"McCollister","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"R36-20230925","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.fertnstert.2011.11.044","article-title":"A cost-effectiveness analysis of Surgical versus medical management of early pregnancy loss","volume":"97","author":"Rausch","year":"2012","journal-title":"Fertil Steril"},{"key":"R37-20230925","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2006-2386","article-title":"Cost of hospitalization for preterm and low birth weight infants in the United States","volume":"120","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"R38-20230925","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jsat.2017.09.012","article-title":"Design and impact of bundled payment for detox and follow-up care","volume":"82","author":"Quinn","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"R39-20230925","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/0193841X12450164","article-title":"The economic cost of substance abuse treatment in the state of Florida","volume":"36","author":"Alexandre","year":"2012","journal-title":"Eval Rev"},{"key":"R40-20230925","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"R41-20230925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/pd.494","article-title":"Preference assessment of prenatal diagnosis for Down syndrome: is 35 years a rational cutoff?","volume":"22","author":"Grobman","year":"2002","journal-title":"Prenat Diagn"},{"key":"R42-20230925","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1360-0443.2010.03001.x","article-title":"Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial","volume":"105","author":"Polsky","year":"2010","journal-title":"Addiction"},{"key":"R43-20230925","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care","volume":"27","author":"Schackman","year":"2012","journal-title":"J Gen Intern Med"},{"key":"R44-20230925","first-page":"511","article-title":"Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women\u2019s preferences","volume":"96","author":"Kuppermann","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R45-20230925","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpeds.2009.01.040","article-title":"Improving decision analyses: parent preferences (utility values) for pediatric health outcomes","volume":"155","author":"Carroll","year":"2009","journal-title":"J Pediatr"},{"key":"R46-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11090","article-title":"Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technol Assess"},{"key":"R47-20230925","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Newmann","year":"2014","journal-title":"N Eng J Med"},{"key":"R48-20230925","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R49-20230925","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/AOG.0b013e31820a6216","article-title":"Substance abuse reporting and pregnancy: the role of the obstetrician-gynecologist. Committee Opinion No. 473. American College of Obstetricians and Gynecologists","volume":"117","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R52-20230925","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/bmj.326.7396.959","article-title":"Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study","volume":"326","author":"Strang","year":"2003","journal-title":"BMJ"},{"key":"R53-20230925","doi-asserted-by":"crossref","first-page":"139.e1","DOI":"10.1016\/j.ajog.2010.10.004","article-title":"Methadone and perinatal outcomes: a retrospective cohort study","volume":"204","author":"Cleary","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R54-20230925","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ADM.0000000000000092","article-title":"Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study","volume":"9","author":"Meyer","year":"2015","journal-title":"J Addict Med"},{"key":"R55-20230925","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/EDE.0000000000000780","article-title":"Methadone versus buprenorphine for opioid use dependence and risk of neonatal abstinence syndrome","volume":"29","author":"Lemon","year":"2018","journal-title":"Epidemiology"},{"key":"R56-20230925","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1542\/peds.2013-3524","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","journal-title":"Pediatrics"},{"key":"R57-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.11.013","article-title":"Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome","volume":"79","author":"Jones","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"R58-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(01)00206-9","article-title":"Reductions in non-fatal overdose after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS)","volume":"22","author":"Stewart","year":"2002","journal-title":"J Subst Abuse Treat"},{"key":"R59-20230925","first-page":"795","article-title":"Comprehensive care of the pregnant addict and its effect on maternal and infant outcome","volume":"1","author":"Finnegan","year":"1971","journal-title":"Contemp Drug Probl"},{"key":"R60-20230925","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0002-9378(72)90777-6","article-title":"Heroin addiction during pregnancy","volume":"113","author":"Statzer","year":"1972","journal-title":"Am J Obstet Gynecol"},{"key":"R61-20230925","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMra1600879","article-title":"Neonatal abstinence syndrome","volume":"375","author":"McQueen","year":"2016","journal-title":"N Engl J Med"},{"key":"R62-20230925","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/AOG.0000000000001152","article-title":"Trends in stillbirth by gestational age in the United States, 2006\u20132012","volume":"126","author":"MacDorman","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R63-20230925","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1605566","article-title":"Survival and neurodevelopmental outcomes among periviable infants","volume":"376","author":"Younge","year":"2017","journal-title":"N Engl J Med"},{"key":"R64-20230925","first-page":"1","article-title":"Infant mortality Statistics from the 2013 period linked birth\/infant death data set","volume":"64","author":"Matthews","year":"2015","journal-title":"Natl Vital Stat Rep"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T22:00:34Z","timestamp":1695679234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003503"}},"subtitle":["A Cost-Effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003503","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}